A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations

NCT05907304 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

86

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced or Metastatic Solid Tumors

Interventions

DRUG: Naporafenib
DRUG: Trametinib

Sponsor

Erasca, Inc.